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Abstract
Background: Microparticles (MPs) stimulate inflammatory adhesion molecule expression in systemic vascular
diseases, however it is unknown whether circulating MPs stimulate localized ICAM-1 expression in the
heterogeneically distinct pulmonary endothelium during pulmonary arterial hypertension (PAH). Pulmonary vascular
lesions with infiltrating inflammatory cells in PAH form in the pulmonary arteries and arterioles, but not the
microcirculation. Therefore, we sought to determine whether circulating MPs from PAH stimulate pulmonary artery
endothelial cell-selective ICAM-1 expression.
Results: Pulmonary artery endothelial cells (PAECs) were exposed to MPs isolated from the circulation of a rat
model of severe PAH. During late-stage (8-weeks) PAH, but not early-stage (3-weeks), an increase in ICAM-1 was
observed. To determine whether PAH MP-induced ICAM-1 was selective for a specific segment of the pulmonary
circulation, pulmonary microvascular endothelial cells (PMVECs) were exposed to late-stage PAH MPs and no
increase in ICAM-1 was detected. A select population of circulating MPs, the late-stage endoglin + MPs, were used
to assess their ability to stimulate ICAM-1 and it was determined that the endoglin + MPs were sufficient to
promote ICAM-1 increases in the whole cell, but not surface only expression.
Conclusions: Late-stage, but not early-stage, MPs in a model of severe PAH selectively induce ICAM-1 in pulmonary
artery endothelium, but not pulmonary microcirculation. Further, the selected endoglin + PAH MPs, but not
endoglin + MPs from control, are sufficient to promote whole cell ICAM-1 in PAECs. The implications of this work
are that MPs in late-stage PAH are capable of inducing ICAM-1 expression selectively in the pulmonary artery.
ICAM-1 likely plays a significant role in the observed inflammatory cell recruitment, specifically to vascular lesions in
the pulmonary artery and not the pulmonary microcirculation.
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Background
Increased numbers of microparticles (MPs) are evident in
pulmonary arterial hypertension (PAH) patients and
animal models, and specific populations of the extracellu-
lar vesicles, such as endoglin-positive MPs, correlate with
disease severity [1–3]. MPs are implicated in pulmonary
vasoreactivity and stimulation of vascular remodeling in
pulmonary hypertension [4–6]. Recent emphasis has been
placed on the importance of infiltrating inflammatory cells
in the formation of pulmonary vascular lesions. These
cells include macrophages, T and B lymphocytes, and mast
cells. However, the mechanisms responsible for the local-
ized transmigration of these inflammatory cells into the
perivascular tissue remains unknown [7]. Cellular adhe-
sion molecule expression is enhanced by proinflammatory
MPs [8–10]. Further, endothelial inflammation promoted
by MPs can lead to enhanced endothelial-leukocyte inter-
actions [8, 10–12]. Thus, we propose that circulating MPs
in PAH contribute to the recruitment of leukocytes to
specific sites of pulmonary vascular lesion formation.
In the pulmonary circulation, heterogeneity exists
between endothelial cells in the macrovascular and
microvascular segments. Although they reside in close
proximity to one another, pulmonary artery endothelial
cells (PAECs) and pulmonary microvascular endothelial
cells (PMVECs) are molecularly and functionally distinct
[13, 14]. PMVECs create an endothelial monolayer with
a more restrictive barrier, and certain agonists are
capable of activating PAECs without a measurable effect
on PMVECs [14]. It has been assumed that MPs will
affect all endothelium in a similar manner, however,
based on evidence of endothelial heterogeneity, it is
likely the responses to MPs will be vascular site specific.
Cellular adhesion molecules are important for immune
cell attachment and migration into lung tissue. The ex-
pression of intercellular adhesion molecule-1 (ICAM-1)
influences the adhesion of circulating immune cells to
the pulmonary endothelium and, therefore, contributes
to immune cell migration and perivascular infiltration.
ICAM-1 on endothelial cells binds to leukocyte function-
associated antigen-1 (LFA-1) and the macrophage-1 antigen
(Mac-1). The protein is expressed constitutively on several
cell types, but ICAM-1 is increased significantly in response
to many proinflammatory signals [15]. Circulating, or
soluble, ICAM-1 is increased in patients with PAH as is
expression of ICAM-1 on endothelium of pulmonary
arteries [16, 17]. Soluble ICAM-1 is present in circulations
of healthy individuals, but the levels are increased in path-
ologies involving endothelial activation. Therapeutics for
PAH patients, such as bosentan, reduce elevated levels of
soluble ICAM-1 along with other inflammatory cytokines
and improve 6-min walk distances [18]. Thus, ICAM-1 and
the inflammatory cells recruited to the sites of its expres-
sion likely contribute to PAH complications in patients.
Considering increased counts of MPs, the proinflam-
matory state in PAH, and the heterogeneity of the
pulmonary vascular endothelium, the purpose of this
study was to determine whether MPs from severe PAH
are a proinflammatory stimulus for pulmonary endothe-
lial cells in a segment specific manner. Since the ob-
served pulmonary vascular lesions in PAH are localized
to arteries and small arterioles, but not the microcircula-
tion, we examined the response to MPs in the pulmon-
ary artery endothelial cells and pulmonary microvascular
endothelial cells. Pulmonary endothelial cells were
exposed to MPs from the Sugen/Hypoxia/Normoxia rat
model of PAH. We investigated the presence of intercel-
lular adhesion molecule-1 (ICAM-1) in both PAECs and
PMVECs to determine if the two cell types had unique
responses to circulating PAH MPs.
Methods
Animal model
All experimental procedures were approved by the
Institutional Animal Care and Use Committee at the
University of South Alabama (Protocol # 829408, PI
Natalie Bauer; Association for Assessment and Accredit-
ation of Laboratory Animal Care International approved
since 1999; Compliance with Public Health Service
Policy on Humane Care and Use of Laboratory Animals
Assurance Number: A3288-01). Adult male Sprague-
Dawley rats (Harlan Laboratories, Inc.) weighing 200–225 g
were randomly assigned to one of two treatment groups.
Control rats were housed in normoxia (21 % O2) for the
duration of the experiment. Sugen/Hypoxia/Normoxia rats,
which will be referred to as PAH rats, were administered
subcutaneous injections of Sugen5416 (20 mg/kg, Cayman)
then placed in hypoxia (10 % O2) for 3 weeks. The rats
were removed from hypoxia and placed in normoxia at the
end of the 3 week period. Rats in each group (3–5 per
group) were euthanized at one of two experimental time
points – 3 or 8 weeks. Heparinized blood was collected
from the right ventricle.
MP isolation
MPs were isolated by a series of centrifugations.
Heparinized blood obtained from each rat by cardiac
puncture was first separated by centrifugation at 1500 ×
g for 7 min. The top plasma portion was retained and
centrifuged further at 13,000 × g for 10 min to eliminate
platelets from the samples. Finally, platelet-free plasma
was ultracentrifuged at 100,000 × g, 4 °C for 45 min to
pellet submicron vesicles. A small portion of intact MPs
from each rat was used to determine the protein
concentration prior to in vitro treatments. Briefly, a
microLowry protein assay was performed on MPs sepa-
rated from plasma by ultracentrifugation. Data obtained
by this method were used to determine the amount of
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MP-associated protein per milliliter of plasma from each
rat. For treatments, MPs pelleted by ultracentrifugation
were resuspended in treatment media (DMEM with
10 % fetal bovine serum devoid of MPs and 1 %
penicillin-streptomycin) at a concentration of 50 μg/mL.
MP sorting
MPs were isolated from blood as previously described.
The MP-containing pellet was resuspended in growth
media without phenol or serum MPs. To distinguish the
population of MPs that contain endoglin on their sur-
faces, 2 μg of endoglin antibody (Santa Cruz, #sc-19793)
conjugated with the APEX Alexa Fluor 488 Antibody
labeling kit (Invitrogen, #A10468) was incubated with
MPs for 30 min at 37 °C. Finally, samples were sorted
into unstained and Endoglin-positive populations using
the BD FACSAria III in our institution’s flow cytometry
core. In addition to sorting microparticles, the BD FAC-
SAria III counted the submicron particles as they passed
through. Total and Endoglin +MP counts per 200 μL of
platelet-free plasma were determined from these data.
Endothelial cell culture and treatments
PAECs and PMVECs from the University of South
Alabama’s Center for Lung Biology Cell Culture Core
were used for these studies. Cells were maintained at
37 °C in room air plus 5 % CO2 with Dulbecco’s
Modified Eagle Medium supplemented with 10 % fetal
bovine serum and 1 % penicillin-streptomycin. To study
the effects of MPs from control and PAH rats on endo-
thelial cells, monolayers of PAECs and PMVECs were
washed with PBS then incubated with 50 micrograms of
MPs per 1 mL of treatment media for 6 h at 37 °C.
Additional monolayers of PAECs and PMVECs were
treated in the same manner with treatment media only
and with media containing 3 % supernatant from
activated pulmonary macrophages (AM supernatant; a
generous gift from Dr. Diego Alvarez). Briefly, to gener-
ate AM supernatant rat alveolar macrophages (ATCC)
are cultured overnight and treated with 100 ng/mL LPS
for 18 h. Medium is collected, centrifuged at 500 × g for
5 min and supernatant retained. The supernatant is
centrifuged again at 4000 × g for 10 min and filtered
through a 0.2 um syringe filter into a sterile tube.
Aliquots are stored at −20 °C until use.
Flow cytometry analysis of endothelial ICAM-1
Following a 6-h incubation period, treatment media with
or without MPs was removed from monolayers of
PAECs and PMVECs. Cells were washed with PBS, then
trypsinized to remove them from the cell culture plate.
Centrifugation at 500 × g for 5 min at 4 °C was
performed to pellet the cells. For treated cells used for
whole cell staining, 0.1 % formaldehyde and methanol
fixation buffer (Invitrogen, V25118) was added for
20 min at room temperature to permeabilize the mem-
branes. Intact cells for membrane staining were resus-
pended in PBS and kept on ice during this time period.
Then all cells were pelleted again, washed with PBS, and
incubated with a fluorescein-conjugated ICAM-1 anti-
body for 30 min at 4 °C (R&D systems, FAB5831F).
After antibody incubation, cells were centrifuged again
at 500 × g for 5 min at 4 °C, washed, then finally resus-
pended in 2 % formalin in PBS. Fixed PAECs and
PMVECs were stored overnight at 4 °C. The following
morning samples were run on a BD FACSCanto II flow
cytometer to determine the percentage of treated cells
that were ICAM-1 positive.
Statistics
Statistical analyses were performed in GraphPad Prism
version 5. All data are presented as means with bars
representing the standard error of the means. Two-tailed
t-tests were performed when comparing the means of
two treatment groups. One-way analysis of variance
(ANOVA) tests combined with Tukey’s multiple com-
parison post-tests were used to determine significance in
data sets containing more than two treatment groups.
P-values less than 0.05 were considered significant.
Supplemental data methods
ICAM-1 immunohistochemistry
Formalin-fixed, parrafin-embedded tissue sections were
deparaffinized at 60 °C for 20 min and followed by 2
xylene washes. Sections were rehydrated in a graded
series of ethanol followed by distilled water. After rehy-
dration, tissue sections were immersed in preheated
citrate buffer (Vector Labs; HC-3300) at 90 °C for
20 min for antigen unmasking. Sections were then
washed three times with TBS-T (0.5 % Triton-X) and in-
cubated with Background Buster™ (Innovex; NB306) for
60 min at room temperature to block nonspecific bind-
ing. Tissue sections were incubated overnight at 4 °C
with ICAM-1 antibody (R & D Systems; FAB58315F) at
a dilution of 1:500 in BSA. After additional washing
steps, slides were mounted with Ultra Cruz Mounting
Medium (sc-24941). Slides were viewed using a Nikon A1R
spectral confocal microscope housed in the BioImaging
Core Facility.
Results
MP counts are elevated in PAH rats
Circulating microparticles are increased in patients with
PAH [2, 3]. Therefore, we investigated differences in MP
counts between control and 8-week PAH rats. Submi-
cron vesicles were isolated from the same volume of
platelet-free plasma from control and PAH rats. Flow
cytometry was then used to enumerate total MPs from
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each sample. We found that PAH rats contain an
increased number of circulating MPs per microliter of
platelet-free plasma than do control rats (Fig. 1). Thus,
our PAH rat model mimics human PAH in the elevated
number of circulating MPs.
MPs from late-stage PAH rats increase ICAM-1 in PAECs
PAH is a progressively worsening disease and with the
advent of a progressive model of lesion formation we
have the ability to determine whether early- and late--
stage microparticles impact the pulmonary endothelium.
Circulating MPs can increase the expression of cellular
adhesion molecules in endothelial cells [8, 9]. Thus, we
investigated the ability of circulating MPs from a pro-
gressive rat model of PAH to increase the expression of
ICAM-1 in PAECs. The rat model of PAH used in these
studies exhibits hemodynamic and histological charac-
teristics that worsen with time [19]. Additionally, inflam-
matory cells that accumulate around remodeled
pulmonary vessels are dynamic in this animal model
[20]. Prior studies have shown that at 8-weeks the
hemodynamic profile of this model is severe PAH, the
pulmonary vascular lesions range from concentric
laminar smooth muscle to fully occluded and we
confirmed ICAM-1 expression by staining control and
late-stage PAH lung tissues (Additional file 1: Figure S1).
By flow cytometry methods, we were able to assess the
whole cell (permeabilized cells) and membrane content
of ICAM-1 in PAECs treated with MPs from PAH and
control rats. For each study we used supernatant from
activated alveolar macrophages, containing multiple cy-
tokines, as a positive control for cell responsiveness. We
found that PAECs treated with MPs from 8-week, but
not the 3-week, PAH rats increase ICAM-1 expression
(Fig. 2). MPs from 8-week, but not 3-week, PAH rats
enhanced the membrane surface expression of ICAM-1
in PAECs (Figs. 2a and b). PAECs treated with MPs from
8-week PAH rats also exhibited a two-fold increase in
ICAM-1 in permeabilized cells (whole cell ICAM-1)
compared to those treated with MPs from 8-week con-
trol rats, and further, no whole cell change in ICAM-1
was detected with 3-week MPs (Fig. 2c and d). These
data suggest that MPs in our late-stage animal model of
severe PAH have a significant impact on the inflamma-
tory profile of the pulmonary artery endothelium.
PMVEC ICAM-1 is not increased by MPs from PAH rats
Within the pulmonary circulation exists significant
phenotypic heterogeneity. Pulmonary artery endothelium
and pulmonary microvascular endothelium are unique
with respect to location and responses to a number of
physiologic stimuli [13, 14]. Thus, we examined whether
the circulating MPs at 8-weeks stimulated ICAM-1
expression on the PMVECs. We found that there was no
increase in ICAM-1 staining of PMVECs treated with
PAH MPs (Fig. 3).
Fig. 1 Circulating MP counts are elevated in PAH rats. The number of MPs per microliter of platelet-free plasma was determined using flow cytometry.
Compared to 8-week control rats, the number of circulating MPs is significantly greater in 8-week PAH rats. n = 5 * = p < 0.05
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Endoglin-positive MP counts in 8 week PAH rats
Endoglin is an accessory receptor for members of the
TGF-β receptor superfamily. Endoglin plays a role in
PAH associated with haemorrhagic telangiectasia [3]. In
examinations of MPs from the circulation of PAH
patients, the endoglin-positive population of MPs is
increased [3]. We examined whether the percentage of
the endoglin-positive MPs increased as the PAH pro-
gressed in our rat model. Compared to 3-week animals,
the 8-week endoglin-positive MP population increased
from 20 % to nearly 50 % of the total population of
circulating MPs (Fig. 4).
Endoglin-positive MPs from late-stage PAH rats drive the
increase in whole cell ICAM-1 content in PAECs
To determine whether the endoglin +MPs had a direct
effect on the PAECs cells we sorted MPs from 8-week
PAH animals into endoglin + and endoglin- populations
and used each population to treat PAECs to assess the
specific effects on ICAM-1 content. Whole cell ICAM-1
was increased in PAECs treated with endoglin +MPs
from 8-week PAH rats compared to that in PAECs
treated with unstained, or endoglin-, MPs from the same
rats (Fig. 5a). Whole cell ICAM-1 levels increased to
about two-fold of that of media-treated cells. These data
Fig. 2 MPs from late-stage PAH rats increase the content of ICAM-1 in PAECs. PAECs were treated with 50ug/mL MPs from age matched control rats,
8-week (a), or 3-week (b) severe PAH rats. Surface (non-permeabilized cells) ICAM-1 was analyzed by flow cytometry and represented by representative
dot plots and fold analysis. Whole cell (permeabilized) content of ICAM-1 was also analyzed (c and d; 8-week and 3-week, respectively). Eight-week, or
late-stage, PAH MPs significantly increased both surface and whole cell ICAM-1 in PAECs, whereas 3-week PAH MPs did not. n = 5
* = p < 0.05, ** = p < 0.01
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Fig. 3 MPs from 8-week PAH rats do not alter ICAM-1 on PMVECs. PMVECs were treated with 50ug/mL MPs from 8-week PAH rats. PMVECs were
analyzed by flow cytometry for membrane ICAM-1 and no changes were evident with PAH-MP treatment. As a positive control, AM supernatant
did increase ICAM-1 on PMVECs. n = 3 * = p < 0.05
Fig. 4 Endoglin + MP counts in severe PAH rats. MPs from 3 to 8-week PAH rats were sorted based on their surface expression of Endoglin, and
Endoglin + MPs were counted. We found that there is a significant increase in the number of Endoglin + MPs between 3 and 8-week PAH rats.
n = 6 * = p < 0.05
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mirror the whole cell increase observed in PAECs
treated with the entire population of MPs from 8-week
PAH rats. In contrast, membrane ICAM-1 content was
not significantly elevated in PAECs treated with
endoglin +MPs from 8-week PAH rats (Fig. 5b). Thus,
endoglin +MPs from 8-week PAH rats stimulate an
increase in whole cell ICAM-1 content in PAECs that is
not associated with an increase in membrane content of
ICAM-1.
Discussion
Circulating MPs have recently garnered a great deal of
interest as biomarkers. In PAH specifically, MPs are
increased in total numbers. PECAM and VE-cadherin
positive MPs correlate with increased mean pulmonary
artery pressure and increased procoagulant MPs correl-
ate with disease severity [2, 3]. Further, MPs induce
expression of cellular adhesion molecules, such as
ICAM-1, on systemic endothelium. While significant
perivascular inflammation is observed in the remodeled
and occluded pulmonary arteries of PAH, little is known
about the mechanisms responsible for inflammatory cell
recruitment [7, 8, 21–23]. Thus, we investigated whether
circulating MPs from the Su/Hx/Nx rat model of severe
PAH stimulate localized ICAM-1 on pulmonary endo-
thelium. In the course of our studies we made three
Fig. 5 Endoglin + MPs from 8-week PAH rats increase the whole cell content of ICAM-1 in PAECs. Endoglin + MPs stimulate a two-fold increase
above media-treated PAECs in whole cell ICAM-1 (a, graph in left panel), but no significant change in membrane content (b). n = 4 ** = p < 0.01
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important observations. First, that circulating MPs from
late-, but not early-stage PAH rats stimulated ICAM-1
expression on endothelium. Secondly, that this ICAM-1
expression was localized to the pulmonary arterial, and
not microvascular, endothelium, and further that a select
MP population, endoglin-positive MPs, were sufficient
to induce intracellular ICAM-1 in pulmonary artery
endothelium.
PAH is a progressively worsening disease that is likely
dependent on multiple “hits” during manifestation. Our
finding that 8-week, but not 3-week, MPs stimulated
increased ICAM-1 may be indicative of the changing
population of MPs present in the circulation as PAH
progresses and pulmonary vascular lesions develop.
Though we did not fully characterize the entire circulat-
ing MP populations, our finding that the endoglin-
positive population makes up significantly more of the
total MPs at 8 weeks as compared to 3 weeks supports
this idea. These data also suggest that a longitudinal
analysis of the various populations of MPs from
endothelium may be important in identifying reporters
of endothelial health in PAH.
Endoglin, as an accessory factor for TGF-β, reportedly
plays a role in development of pulmonary arterial lesions
[24, 25]. Endoglin-positive MPs may also be representa-
tive of a damaged or hyperproliferative endothelium
such as that observed in PAH [3]. However, the impact
of select populations of MPs on progression of the
disease has not previously been investigated. We
selected the endoglin + population and found that
without the influence of the total MPs, endoglin +MPs
alone were sufficient to induce increased ICAM-1
protein intracellularly. The effects of MPs, and even
select populations of MPs from cell culture studies, have
been examined on various endothelium, however this is
the first report we are aware of that clearly reveals the
impact of one subset of circulating MPs in PAH. Since
PAH is a progressive and likely “multi-hit” disease, we
can speculate that the endoglin +MPs or their contents
induce ICAM-1 production, but a second “hit” is
required for recruitment to the pulmonary artery endo-
thelial membrane for functional recruitment and adhe-
sion of inflammatory cells.
Endothelial heterogeneity within the pulmonary circu-
lation is defined by location of the cells and their physio-
logic and pathologic responses [14, 26–28]. By testing
endothelial cells derived from both the pulmonary arter-
ial and microcirculations we could identify whether the
circulating MPs affected a specific location. Importantly,
in PAH the pulmonary vascular lesions, containing
inflammatory cell infiltrates, develop in the pulmonary
artery but not in the pulmonary microcirculation. The
8-week circulating MPs did not induce ICAM-1 expres-
sion in or on PMVECs, from the microcirculation. We
cannot state explicitly that the MPs had no effect on the
PMVECS, since we only examined ICAM-1 expression,
and further studies would be necessary to determine
whether there were influences on proliferation or other
inflammatory molecules, however the implications are
intriguing. The concept that MPs interact with cellular
targets has been proposed, but rarely directly tested.
These data leave open speculation on the mechanism of
this “targeting”. Whether the MP possesses proteins or
lipids necessary for interaction specifically with PAECs
rather than PMVECs, or if the cell processes the inter-
action in a unique manner remains unknown. However,
these are some of the first data to address MP effects
using phenotypically distinct endothelium and to show
differential responses. The implications of this work for
PAH are that there are mechanisms inherent to circulat-
ing microparticles that influence the pulmonary artery,
which do not stimulate the pulmonary microcirculation.
A multitude of inflammatory factors have been reported
to be increased in the circulation of PAH patients, but it
has never been understood why the effects are only
observed in specific vascular locations. MPs may contain
the key to targeted vascular damage or even repair,
however many studies will be necessary to answer these
questions.
Conclusions
In summary, our study highlights the impact of circulating
PAH MPs selectively on the pulmonary artery endothelium
leading to expression of both surface and intracellular
ICAM-1. The increased intracellular ICAM-1 can be reca-
pitulated with a selected population of PAH MPs, the
endoglin +MPs, however this population does not increase
surface expression. These are the first data to implicate
PAH MPs, or a select population of circulating PAH MPs,
in pulmonary vessel segment specific expression of ICAM-
1. ICAM-1 likely plays an important role in recruitment of
inflammatory cells to pulmonary vascular lesions in PAH.
Additional file
Additional file 1: Figure S1. ICAM-1 expression is increased in pulmonary
arteries of 8-week PAH rats. ICAM-1 is labeled green, and the blue are DAPI
labeled nuclei. Intense staining is highlighted with red arrows. Control 8-week
rats have limited ICAM-1 staining in pulmonary arteries and alveolar structures.
Eight-week PAH rats have significant ICAM-1 staining in the airway, in
crenelated or constricted pulmonary arteries, and lining open pulmonary
arteries. Images are representative of n= 3 separate animals. (DOCX 5675 kb)
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